Importance COVID-19 has placed a monumental burden on the health care system globally.
Although no longer a public health emergency, there is still a pressing need for effective …

This study leverages electronic health record data in the National COVID Cohort
Collaborative's (N3C) repository to investigate disparities in Paxlovid treatment and to …

Introduction: Previous trials and real-world studies have shown that nirmatrelvir/ritonavir
(Paxlovid®) reduces hospitalisation and deaths in symptomatic, high-risk, nonsevere COVID …

Summary Background Nirmatrelvir plus ritonavir (Paxlovid) reduced the risk of
hospitalization or death by 89% in high-risk, ambulatory adults with COVID-19. We aimed at …

Abstract Title Describing COVID-19 Patients During The First Two Months of Paxlovid
(Nirmatrelvir/Ritonavir) Initiation in a Large HMO in Israel Objective The objective of this …

ABSTRACT Background In the United States, oral nirmatrelvir-ritonavir (Paxlovid™) is
authorized for use among patients aged≥ 12 years with mild-to-moderate SARS-CoV-2 …

Background Our objective was to evaluate the real world effectiveness of
nirmatrelvir/ritonavir to prevent severe COVID-19 while Omicron and its subvariants …

Objective To compare the effectiveness of Paxlovid vs. sotrovimab and molnupiravir in
preventing severe COVID-19 outcomes in non-hospitalised high-risk COVID-19 adult …

Background: In the EPIC-HR trial, nirmatrelvir plus ritonavir led to an 88% reduction in
hospitalization or death among unvaccinated outpatients with early COVID-19. Clinical …

BACKGROUND New COVID-19 oral antiviral treatments–Paxlovid (ritonavir-boosted
nirmatrelvir) 1 and Lagevrio (molnupiravir) 2–were first made available at the end of 2021 …